Dr. Verdin is the President and CEO of the Buck Institute for Research on Aging. His laboratory studies the relationship between ageing and the immune system. A native of Belgium, Dr. Verdin completed his clinical and research training at Harvard Medical School. He has held senior appointments at several international medical schools, and is also a professor of medicine at University of California, San Francisco. Dr. Verdin has extensive experience working with biotech companies, including Novartis, Roche, Pfizer, and now Hooke.